2023 NACLC Program
The IASLC 2023 North America Conference on Lung Cancer (NACLC) runs December 1-3, 2023, at the...
Read MoreNov 22, 2023
The IASLC 2023 North America Conference on Lung Cancer (NACLC) runs December 1-3, 2023, at the...
Read MoreNov 17, 2023
For patients with primary progressive MS, age is a particularly important factor that predicts disease activity.
Read MoreNov 16, 2023
The benefits of interleukin inhibitors vary by agent and include increased drug survival and earlier attainment of Psoriasis Area Severity Index scores.
Read MoreNov 16, 2023
Aflibercept 8 mg shows efficacy for patients with diabetic macular edema regardless of sex, age, and race/ethnicity.
Read MoreNov 14, 2023
Disease-free survival could be predicted by high expression of TGFβ CAF in patients with eNSCLC treated with atezolizumab.
Read MoreNov 14, 2023
Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.
Read MoreNov 13, 2023
Fractal dimensions represent a promising biomarker for assessing retinal vascular damage.
Read MoreNov 10, 2023
Dermatologists must be knowledgeable about differences among people of color with psoriasis and to tailor their approach to diagnosis and treatment accordingly.
Read MoreNov 8, 2023
Progression independent of relapse activity explains why certain patients with MS continue to worsen clinically without MRI evidence of new lesions.
Read MoreNov 2, 2023
“With lung cancer we’re treating more patients effectively today and even curing them because we’re using our most effective therapies earlier.”
Read MoreOct 31, 2023
Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.
Read MoreOct 30, 2023
Check out the key presentations from AAN Fall Clinical on MS. And follow along for more from AAN.
Read MoreOct 27, 2023
Educational and research gaps in treating plaque psoriasis in patients with skin of color can lead to delays in diagnosis and treatment.
Read MoreOct 26, 2023
The following is a summary of “Intravitreal Aflibercept 8 mg for DME: Week 48 Efficacy Outcomes by...
Read MoreOct 26, 2023
The following is a summary of “A Multimodal AI Risk Scoring Model to Predict the Development of...
Read MoreOct 26, 2023
The following is a summary of “Intravitreal Aflibercept 8-mg Injection in Patients With nAMD:...
Read MoreOct 25, 2023
Explore, connect, learn, relax and more at the AAO 2023 Expo. Follow PW for conference updates.
Read MoreOct 25, 2023
AAO Announces The Orbital 2023: Gold Rush Fundraising Event, formerly the Orbital Gala.
Read MoreOct 25, 2023
AAO 2023 is offering a virtual version of their conference. Follow PW for conference highlights.
Read MoreOct 25, 2023
The following is a summary of “Follow-Up Characteristics in a Large Diabetic Teleretinal Screening...
Read More